D
doky69
@doky69
Posts
-
Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results
-
$2.87? What´s up?
-
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for COPIKTRA
(duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).
-
+$1? What´s up?
VSTM
VSTM
VSTM
VSTM
VSTM
VSTM
BIIB